@jamit05 Thanks for highlighting shortcomings. This helps uncover any blind spots. I used to think of myself as a growth investor until a few years back, but my investment philosophy has evolved and I am open to looking at cyclical or low RoE businesses. However, I must admit I don’t have a great track record of getting the business cycle and valuation right.
@Ediacaran97 That makes it two of us, I have been holding Repco since IPO times as well. I do not hesitate to cut losses, but this is one name that has hit many roadblocks over the years. NPAs were always expected to be high and seasonal. However, the absolute write-off numbers from bad assets are encouraging and indicate the markets are not pricing this well as compared to a Canfin. The non-salaried lending will take a hit in the near term, because of the lock-downs that are happening across. At 0.5 book value, the valuation currently is very comforting. However, Repco is at the bottom of my list in terms of the amount of cash I have deployed in this crash, and I intend to keep it like that.
@bharat.jain I haven’t calculated my CAGR yet. My sense is that a good amount of fresh cash deployed since 2018 hasn’t delivered well except for Canfin and a couple of Pharma names.
I deployed a decent amount of cash into FD’s throughout 2nd half of 2019. This used to be 15% of my portfolio, but has now become ~30% thanks to sudden drop in prices of my stocks. I intend to maintain this at 15% now.